Johnson & Johnson Shares - Leerink upgrade and fresh analyst views
21.06.2026 - 08:28:25 | ad-hoc-news.de
Edited by ad hoc news Analyst & Consensus Desk. Verified prior to publication on 06/21/2026, 06:20 UTC. Details in the imprint.
Johnson & Johnson (US4781601046) sits at the intersection of defensive healthcare and ongoing portfolio reshaping. The latest impulse for the stock comes from an analyst move after Leerink upgraded its view and raised its price target, according to a recent analyst summary.
All news and analysis on Johnson & Johnson stock
Key figures, estimates and recent analyst actions on Johnson & Johnson stock are collected in our dedicated topic section.
Leerink turns more positive
According to a recent analyst round-up, Leerink upgraded Johnson & Johnson from Market Perform to Outperform and lifted its price target to $265 from $252, signaling increased confidence in the company’s earnings profile and pipeline potential. The analyst summary citing the Leerink move highlights the stock as a relatively stable alternative to high-beta technology names.
The raised target implies upside from the current share price region around the low-$230s and positions Johnson & Johnson as a core defensive holding in a market still dominated by growth narratives. Recent market data pages show the shares changing hands just below the new target benchmark.
How Wall Street values Johnson & Johnson
Beyond Leerink, the broader analyst community continues to view Johnson & Johnson as a large-cap healthcare anchor with robust free cash flow and a long dividend history, even after the separation of its consumer health business Kenvue. Company investor materials emphasize pharmaceuticals and MedTech as the main growth drivers.
Consensus numbers compiled by major financial data platforms cluster around a Buy to Hold stance, with price targets typically implying mid-single-digit to low double-digit upside from current levels. Aggregated analyst estimate pages indicate a blended target area in the mid-$250s, while earnings expectations assume steady single-digit revenue growth.
The product lines behind the stock
Johnson & Johnson today generates the majority of its revenue from its pharmaceutical segment, branded as Janssen, with key products such as Stelara for immune-mediated inflammatory diseases and Darzalex for multiple myeloma, complemented by a sizable medical devices portfolio spanning orthopedics, surgery and cardiovascular interventions. Annual report materials outline how these franchises underpin long-term cash flows.
Where the stock trades today
Johnson & Johnson shares (US4781601046) last traded on the New York Stock Exchange at $228.37 as of 06/18/2026, 15:59 Eastern Time.
Johnson & Johnson at a glance
- Company: Johnson & Johnson Inc.
- ISIN: US4781601046
- WKN: 853260
- Ticker: JNJ
- Venue: NYSE
- Price (as of 06/18/2026, 15:59 ET): 228.37 USD
- Market cap: 438,000,000,000 USD (as of 06/18/2026)
- Sector / Industry: Health Care / Pharmaceuticals & Medical Devices
- Index membership: Dow Jones Industrial Average, S&P 500
- Next earnings date: 07/18/2026
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
